Drugs / Krytantek Ofteno®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03257813 | Apr 2016 → Mar 2017 | ocular hypertension, open-angle glaucoma | Laboratorios Sophia S.A de C.V. | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03966365 Comparator | May → Aug 2019 | glaucoma | Laboratorios Sophia S.A de C.V. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Krytantek Ofteno | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03966365 ↗ |
| Route | Other | “Patients will receive 1 drop B.I.D. into the lower conjunctival sac of either formulations” NCT03257813 ↗ |